Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice

BACKGROUND: The capacity of the recombinant Vaccinia virus GLV-1h68 as a single agent to efficiently treat different human or canine cancers has been shown in several preclinical studies. Currently, its human safety and efficacy are investigated in phase I/II clinical trials. In this study we set ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofmann, Elisabeth, Weibel, Stephanie, Szalay, Aladar A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105246/
https://www.ncbi.nlm.nih.gov/pubmed/25030093
http://dx.doi.org/10.1186/1479-5876-12-197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105246/
https://www.ncbi.nlm.nih.gov/pubmed/25030093
http://dx.doi.org/10.1186/1479-5876-12-197

Ejemplares similares